InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 151498

Monday, 12/09/2013 9:13:02 PM

Monday, December 09, 2013 9:13:02 PM

Post# of 346720
Monoclonal Antibodies... Big Pharma... Big Profits... in comes Google Ventures- Bill Maris and maybe he is a little sick and tired of jump starting small biotechs and failing to get a return on investment that provides a big "moonshot" for his portfolio...

...so what to do ? Start "Calico" and take all that money from Google Ventures that you were placing into companies such as "Adimab" and create something that will give you that "moonshot" of a chance at becoming larger than Big Pharma itself.

New details on Google's anti-aging startup

Oct 9, 2013


So I did a bit of digging while in Silicon Valley last week, and have learned much more.

Calico is considered the brainchild of Bill Maris, the Google Ventures managing partner who once was a biotech portfolio manager at Investor AB. Sources says that Maris looked at the life sciences landscape, and saw hundreds of companies all focused on curing or minimizing various diseases and conditions. In all cases, the goal was either to prolong life and/or improve the quality of life.

http://finance.fortune.cnn.com/2013/10/09/new-details-google-anti-aging/


--------------------------------------------------------------

Lets take a step back and look at a company such as "Adimab" - backed by some start up money... some of that from "Bill Maris"

Adimab - BOD ... includes "Bill Maris"

http://www.adimab.com/about-adimab/adimab-board-of-directors/

-------------------------------------------------------------

What do I think? I believe Bill Maris has seen and experienced "ENOUGH" of how Big Pharma works, how "partnerships" work and how "collaborations" have been working that why should he invest in these companies where he has no control... even on the BOD... so here comes Calico. My best educated guess is its not going to be betting the house on one company or one partnership but you do need a foundation platform and that platform will be.....very possibly Peregrine Pharmaceuticals "PS targeting platform" : )

Bill is the managing partner and founder of Google Ventures, where he oversees all of the fund’s activities. Bill sits on the boards of Nest and Adimab.

Bill conceived of the business plan for Calico, a new healthcare company focused on aging and related diseases.

http://www.gv.com/team/bill-maris



-------------------------------------------------------------

Adimab partners - guess who is missing..? BMS

http://www.adimab.com/adimab-partners/

-------------------------------------------------------------

Whats more important here is that Anderson (COO and co-founder of Adimab) all made Adimab work by partnerships and VC seed money ... but guess what ? The company management and employees own less than 50% of Adimab. The other 50%+ is owned by the VC's and partners (Big Pharma Partners) -- VS -- Peregrine who owns 100% of Peregrine... this is what pi$$es off the opposition the most. They (Big Pharma...etc ) were never able to get a handle around Peregrine so operation Fargo plan B

Before Anderson dove full time into Adimab he did his summer internship in marketing for Bristol-Myers Squibb (BMS). Working in a large corporation can be good experience, he said, even if being an entrepreneur is your ultimate goal. While at BMS, for example, Anderson used his credentials to speak with researchers at firms who wouldn’t have given him the time of day if he were an independent person. He then used that knowledge to inform his work at Adimab.

http://www.tuck.dartmouth.edu/entrepreneurship/news/errik-anderson-kicks-off-entrepreneur-in-residence-program

-------------------------------------------------------------

More importantly.... guess who was part of Adimab and knows "ENOUGH" about Mabs / legal / USPTO ... and joins BMS in Sept 2012 "Sr VP Business Development" to secure partnerships /collaborations/buyouts..etc.?

Fran Heller... and remember all those collaborations that Adimab had going and BMS was out of the loop? Sounds like a perfect way to hire Fran Heller and its all about what you know and who you know....

http://www.linkedin.com/pub/fran-heller/1/133/71

http://www.bms.com/ourcompany/leadership/Pages/frances-heller-bio.aspx

-------------------------------------------------------------

Who will back Peregrine? I say CALICO should... its a win-win for both sides. CALICO will be transferring much of their small biotech backed VC seed money right into their own company for a control of assets they never had before. In Art Levinson, Dr. Robert Garnick and SK & company shall trust.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News